CD276 and neoplasm: The FGFR4.28HTM.28z-CD276.8HTM.BBz BiCisCAR T-cells demonstrated superior tumor-killing activity than those of FGFR4.28HTM.BBz-CD276.8HTM.BBz in vitro (Fig. 3F).